Trial Profile
A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Phase 3b Study to Assess the Safety and to Describe the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination (IV NEPA FDC) Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination (Akynzeo) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Initial and Repeated Cycles of Anthracycline-cyclophosphamide (AC) Chemotherapy in Women With Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Netupitant/palonosetron (Primary) ; Dexamethasone; Netupitant/palonosetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Helsinn Healthcare SA
- 04 Jan 2023 According to an Helsinn Media release, results from secondary analysis have been published in The Oncologist.
- 04 Jan 2023 Results from secondary analysis published in the Helsinn Media Release.
- 11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium